PO Box 823 Dunedin New Zealand
TOREA TECHNOLOGIES IS ENGAGED IN RESEARCH, DESIGN AND DEVELOPMENT OF AERODYNAMIC SYSTEMS,PRODUCTION AND DELIVERY OF BIOTECHNOLOGY DERIVED PHARMACEUTICALS IN LUNG CANCER AND INFLUENZA
TWO PRODUCTS ARE CURRENTLY DEVELOPED FOR HEALTH CARE APPLICATIONS
THE TOREA NEBULIZER
THE TOREA INFLUENZA PROTECTANT
A Protectant Against Aerodynamic Influenza Transmission and Infection via the Lung eg H1N1
-Presentation of a malleable packing of desiccant spheres to form an exclusion pathway to prevent inhalation of coughed droplets with minimal breathing resistance
A flu protectant is developed which if used in conjunction with nose breathing is able to impede, immobilize and prevent the access and spread of aerodynamic aqueous aerosols of expelled respiratory secretions containing pathogens such as viruses and prevent transmission from a contagious host of the disease produced by their coughing, protecting transmission and infection to another potential human host and offers an alternative to a mask with a number of advantages.
Nasal breathing is widely accepted as the optimal breathing manoeuvre to force inspired air through the nose and it's turbimetric conchae filtration as opposed to mouth breathing which bypasses filtration and is described in yoga and occupational exposure studies to have many benefits from filtration and purify the air before it reaches the lungs for gaseous respiratory requirement. Direct inhalation through the mouth exposes one to a high risk situation and needs to be avoided and the effectiveness of the Torea Influenza Protectant relies on nasal breathing.
Virus laden coughed aqueous mists allow an affinity to desiccant adsorbents as a first line contact and immobilization with droplets rather than naked bacteria or viruses presented as an inhaled insult.
Normally the natural filtration is directed towards dry airbourne matter such as pollen and dust.
The Torea Influenza Protectant directs the inhalation filtration towards aqueous specificity and extraction of the airbourne droplets.
Customizably malleable the biocompatible pack of silica gel spheres is able to occupy the nares providing a channeled tortuous hygroscopic air passage for breathing with minimal resistance. A resultant packed configuration fitting each nostril and accommodating accompanying physiology conjectured variation provides an exclusion pathway for air with the customized spherical packing arrangement.
Two protectant units cosmetically skin toned are inserted externally in to the nose and fitted gently into each nostril and packed with the malleable sealing properties to allow inspired air containing contagious aqueous droplets to pass through a tortuous pathway of hygroscopic and adsorbent granules with resultant extraction and purification of the air. Gentle manipulation pressure allows protectant to meld into the nostril cavity and remain within. With this protectant access to the lung is prevented and influenza can be stopped from spreading and find a use to trap aqueous coughed aerosols breathed in from proximity of a contagious host and impede transmission and spread of aqueous based influenza droplets which must be inhaled and deposited and pass into the lung epithelium and be absorbed to complete their life cycle.
Proximity of a person to exposure to infectious situations are frequently encountered in many day to day activities from sleeping, cold, transport,co-habitation and nursing situations and high exposure risk is exacerbated by advent of numbers involved with estimates of up to 40% of the population succumbing and alarm is expressed with the advent of avian influenza and possible evolved transmission from person to person. Viruses, bacteria, fungi and intercepted pathogens are also of concern with secondary and opportunist infection as a consequence of the primary infection upon inspiration in a potential host. Health workers are frequently exposed to different types with occupational contact and caring for victims of influenza with associated contagious aerosol mists generated rapidly and repeatedly with persistent coughing and secondary infection and co-pathology such as asthma and can be overwhelming in a closed environment with transient exposure circumstances. Masks are designed to block both expiratory and inspiratory air for mouth and nose breathing and are not reliable for sealing with jaw movement eg talking and also have an intimidating appearance.
A Disposable and low cost product available in a sealed multiunit pack presentation able to be carried on ones person and opened individually with ingredients sourced from Pharma grade sources and produced in a clean packaging facility and are for external use only. Packaging utilizes sanitary open weave porous outer with a fine piece of fibre attached to aid removal resulting in a mini happysack tea bag/ appearance.They become exhausted within twelve hours and need to be replaced with careful disposal of the old ones. Protectants can be added to a first aid kit and can be carried on one's person and inserted very quickly when a transient high risk exposure situation such as a close range cough from a contagious host presents itself.
Pandemic and community transmission with currently a large number of influenza viruses identified with sentinel and laboratory based surveillance with haemaglutinin and neuramidase antigenically typed variants has resulted in morbidity planning such as the NZ Ministry of Health Pandemic Plan and United Nations World Health Organization Preparedness Strategies being in place for avian influenza. Other viruses and pathogens are also of import to the community and cause considerable morbidity.
In contemporary health pathogenicity large numbers of viruses are replicated with infection and with increasing pathogenic and mutation capacity eg H1N1 from selective evolution and are transmitted in inhaled aqueous aerosol mists generated from coughing into the air with propulsion of respiratory secretions of both extra and intracellular particulates. Coughed aqueous aerosol droplets are able to be loaded with considerable numbers of viruses estimated at up to ten million per droplet and can remain viable in this unique bioformulation and also contain other forms of pathogens and factors such as colloidal surfactants and buffers and remain suspended in the atmosphere for some time. These expelled droplets rapidly form aqueous spheres of various sizes in the air from surface tension and weightlessness and are aerodynamically suspended in airstreams. Uniquely aqueous the virus laced aerosol mist droplets present an affinity to a desiccant adsorbent as a first line contact and immobilization and consequently exposure to prolonged mucous bioattack from the inhalation protectant in the nostril and subsequent physical removal and disposal.
Each nostril does not necessarily present a related symmetry or mirror of its other nostril partner in terms of aerodynamic shape or accompanying physiology and requires a custom fit with a malleable form as a flexible semi-solid matrix allowing tortuous air flow though a network of crystals with aqueous and adsorbent hygroscopic affinity consisting of silica gel in a permeable type barrier to separate and immobilize aqueous aerosol mist droplets. Each protectant of the pair is able to form a seal if malleably fitted in it's nostril and is able to present a barrier in the transmission cycle of the lung to lung of viral infection.
ABSTRACT WIPO PCT/NZ2008/
A PROTECTANT AGAINST AQUEOUS AERODYNAMIC INFLUENZA TRANSMISSION
A protectant used with nose breathing can prevent the inhaled access of coughed aerodynamic aqueous aerosols of expelled respiratory secretions containing pathogens. Virus laden mists allow an affinity to desiccant adsorbents as a first line contact and immobilization with droplets rather than naked bacteria or viruses presented as an inhaled insult. Customizably malleable a biocompatible pack of silica gel spheres is able to occupy the nares providing a channeled tortuous hygroscopic air passage for breathing with minimal resistance. A resultant packed configuration fitting each nostril and accommodating accompanying physiology variation provides an exclusion pathway for air with the customized spherical packing arrangement. A disposable blister pack pair in a first aid kit or carried on one's person can be inserted and malleably packed quickly into the nostrils with the fingers when a transient exposure situation such as a close range cough from a contagious host presents such as H1N1 influenza.
NZ Patent Application 572276
Mark P Best
October 2008
A nebulizer unit driven by low pressure pump or cylinder and a mist produced of one micron diameter from small volumes of less than 0.5ml of feed solution and a lag volume of less than 0.05ml contributing to it's efficiency and lending itself to nebulization and respiratory delivery of expensive and researched agents such as those produced pharmaceutical chemistry and biotechnology.
NZ Patent 544519
Mark P Best
Journal No 1550 August 2008
Clinical Design Features
Designed for micromist production with aerosol droplet size less than 1 micron ensuring peripheral delivery
Small Volume capability Less than 0.5ml
Efficient Nebulization Rate 0.2ml/min
Small lag volume Less than 0.05ml
Self Cooling airjet operation with horizontal air feed
Precision Output Specification with direct microscopic measurement
Novel gentle aerosolization mechanism with
an aerodynamic nozzle
Low Pressure Operation 8-10l/min domiciliary pump or cylinder Produces a moving aerosol stream
Easier to entrain and direct. Allows inhalation delivery requiring less patient effort and dead space lag losses
Solid State Construction
Resealable,Robust,No Moving Parts and safe to use in theatre atmosphere
Storage in Purpose built base…dosimetric weighing capability for multidose administration.
FEATURES—A DRUG DELIVERY DEVICE
Produces moving stream of mist..easier to breathe from...better lung deposition
Clinic Use..dosimetric when used with storage base and a four figure digital balance..weigh unit before and after
Particle size small..less than 1 micron..ensures peripheral airways penetration
More efficient 0.2ml/min Nebulization rate
Handles very small volumes...allows doses of less than 0.5ml to be administered
Small lag volume..less than 0.05ml.
Resealable for storage
Robust,reusable
BIOMEDICAL NEBULIZER DELIVERY APPLICATIONS
Biotechnology derived products…
Antibiotics... Bird Flu
Antiasthmatics…
Antivirals…...HIV Infection
Mucolytics...DNAse, etc
Enzymes,peptides,proteins
Potent agents… radiopharmaceuticals, bioactive pharmacological agents Antibodies...Cancer specific... epithelial lung specific
Nicotine
Vaccines Vectors
MISTING AND SPRAYING
Plates,gels,surfaces
Chromatography
Developers
Amplifications
Humidification
Fumigation
AERODYNAMIC NOZZLE
AEROSOL OUTPUT 
AEROSOL MIST GENERATION AND SIZE SELECTION MECHANISM UTILIZED IN THE TOREA NEBULIZER
MIST GENERATION-GENERATION OF AN AERODYNAMIC FLOWFIELD
With high incidence airflow passing over a nozzle body in the aerosolization chamber air is drawn down into the space in the aerodynamic shadow of this aerofoil wing nozzle shape and turns inwards and downwards into a generated circulatory microvortex flow drawing and suctioning fluid from the reservoir into the microflowfield. Filamentous shedding of fluid is achieved with the aerodynamic nozzle to produce the mist.
SIZE SELECTION AND AEROSOL PRODUCTION UTILIZED BY THE TOREA NEBULIZER
Staged separation of fine mist droplets in the flowfield is based on angular momentum and passage of a moving stream of mist to separate larger droplets. ... Interception is achieved by the powered vortex rotation, ground effect,reflection and passage through the aerosolization chamber and with moving stream and angular momentum effects to separate the fine mist. The larger droplets extracted from the mist drop back down to the reservoir to be recycled through the aerosolization mechanism.
Clinical Use
To optimize deposition
Patient breathing technique is important ..fast shallow mouth breathing to be avoided
Gargling after Administration
Clamp nose
Care of nebulizer
Not disposable ..sanitize...wash..hot water
CLINICAL UTILIZATION
Mucociliary Clearance 4hrs
Lung Cancer Using Nebulized
Biotechnology Derived
Antibodies For Early Detection imaging
Lung cancer
pathology
Lung cancer is the leading form of cancer death in the US. In 1992 there
were about 168,000 new cases of the disease diagnosed and approximately
146,000 deaths attributed to it. This number is increasing and many cases
are not diagnosed until fairly advanced due to the rapid rate of tumor
growth,soft tissue differentiation identification difficulties with
cytology sampling, radiology and deep fine structure location in the
bronchial tree. Location of cancers occur frequently at bronchial tree
bifurcation points with aerodynamic interception of inhaled carcinogenic
particulates such as tar from cigarette smoke.
Such is the burden on health care resources that tobacco litigation
settlements resulted in $230 billion recently.
Current lung cancer
detection
For the patient the problem has been to detect and diagnose malignant from
harmless lesions and in the US 40,000 resultant invasive exploratory
thoracic surgical operations(thoracotomies) requiring risky full theatre
resection workup and recovery with these investigations are found to be
inappropriate for them. In these cases the bronchial wall lesions can be
benign resulting from other etiology e.g. inflammation,infection and
fibrosis or part of unresectable disease and disseminated. Other options
for inoperable disease that has spread include chemotherapy and palliative
measures.
New imaging technology
A new imaging technology has been developed in Dunedin New Zealand to
photograph epithelial lung cancer by inhalation delivery and localization
of a biospecific contrast tracer. The procedure is simple and
non-invasive involving breathing of a mist and offers imaging with cancer
for early and more specific detailed photography available at hospital
imaging centres on an outpatient basis using currently available ethically
approved clinical materials and procedures. The inhaled biospecific
contrast agent is able to recognize epithelial lung cancer and localize by
antibody reaction carrying the imaging agent with it once inside the lungs
and deposited on the lung epithelium. The resultant images can be used in
treatment planning eg radiotherapy targeting from early diagnosis and
screening.
Inhalation of the biospecific mist is an efficient direct delivery
means achieved with nebulizer produced aerosol having microfine droplet
dimensions to achieve deep lung penetration. Coating of the considerable
surface of the bronchial tree occurs beyond the range of the bronchoscope
in depth and spatially within airways architecture.
Biospecificity of
monoclonal antibodies
Differentiating malignant from innocent lesions is achieved by the
monoclonal antibody based tracer which has fine tuned recognition
properties based on a molecular level. Antibodies are utilized in the body
as a protection and recognition means e.g. flus and immunity and have
offered optimism in oncology since their discovery and Nobel Prize winning
biotechnological development. Application of these is widespread and
cytology of tumor tissue identification in sputum and biopsy samples is
used extensively in bioseparation technologies. Monoclonals and
recognition derivatives are now available as pharmaceutical products with
high purity and in quantity from the biotech industry and stock market
investment. Labeling and imaging utilizes the clinical tracer Technetium
used extensively in hospital nuclear medicine clinics and nebulizer
produced aerosol for routine ventilation studies .
Epithelial lung cancers have tumor specific characteristics and the antibodies selected are able to recognize these and immunoreact. Contrast enhancement then occurs with mucociliary clearance sweeping out the unreacted agent from the lung fields and background subtraction for the image process. This natural clearance develops biologically based imaging photographs showing location and extent of the cancer. Mucociliary clearance in participation with lung fine structure acts as a powerful filtration mechanism for our inhaled air.
Mucociliary Clearance
Naturally sweeps out
inspired air filtered matter
-four hour image shows up
bronchii-nb heart displacement on left hand side
-lowers image background
resolving and revealing tumor associated
cancer location
-effects concentration
dynamics
Images
and
text copyright 